EUVIMEDEUVIMED entdecken
Crossref

Racial, ethnic, and biologic sex disparities in outpatient laboratory monitoring of isotretinoin use: a cross‐sectional study

Divya Manoharan, Nancy Nkansah-Mahaney, Anna Chien

International Journal of Dermatology · 2024

DOI: 10.1111/ijd.16961 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Dermatology, 2024. Verfasst von Divya Manoharan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins University School of Medicine, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Dermatologic Agents, Acne Vulgaris, COVID-19, Biological Products. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 4 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Isotretinoin is commonly used for the treatment of acne. Despite high efficacy, isotretinoin has a side effect profile that prompts regular outpatient laboratory monitoring. Emerging evidence suggests clinically significant lab abnormalities are rare. Racial, ethnic, and biologic sex disparities in laboratory monitoring of isotretinoin have yet to be characterized.

Methods

This study explores disparities in laboratory monitoring of patients prescribed isotretinoin, factoring in the COVID‐19 pandemic given its impacts on laboratory monitoring. Two populations were evaluated: all patients taking isotretinoin, and patients taking isotretinoin with no metabolic, cardiovascular, hematologic, hepatic, or renal comorbidities. The latter population was included to screen out patients who might receive increased laboratory testing for conditions besides isotretinoin use.

Results

Our data reveal that African‐American, Asian, and Hispanic patients prescribed isotretinoin were more likely than Caucasian patients to receive orders for outpatient laboratory monitoring. These disparities persisted independent of comorbidities that may prompt additional testing, suggesting that non‐Caucasian patients bear an additional testing burden even when their comorbidities were matched to their peers. Disparities persisted in the setting of reduced laboratory monitoring due to the COVID‐19 pandemic.

Conclusions

These data reveal that patients of color are more likely to receive outpatient laboratory monitoring for isotretinoin prescriptions. There is an opportunity for testing standardization to improve medication access, decrease burden and costs for patients and the healthcare system, and decrease racial disparities in prescribing and monitoring of isotretinoin. Dermatology clinics may benefit from standard operating procedures outlining for whom regular monitoring is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatologic AgentsAcne VulgarisCOVID-19Biological ProductsHumansIsotretinoinCross-Sectional StudiesOutpatientsPandemics

Substanzen

IsotretinoinDermatologic AgentsBiological Products

Autor:innen und Institutionen

  • Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Johns Hopkins Hospital Department of Dermatology, Baltimore, MD, USA.

Zitieren

APA

Manoharan, D., Nkansah-Mahaney, N., & Chien, A. (2024). Racial, ethnic, and biologic sex disparities in outpatient laboratory monitoring of isotretinoin use: a cross‐sectional study. International Journal of Dermatology. https://doi.org/10.1111/ijd.16961

Vancouver

Manoharan D, Nkansah-Mahaney N, Chien A. Racial, ethnic, and biologic sex disparities in outpatient laboratory monitoring of isotretinoin use: a cross‐sectional study. International Journal of Dermatology. 2024. doi:10.1111/ijd.16961

BibTeX
@article{Manoharan2024,
  author = {Manoharan, Divya and Nkansah-Mahaney, Nancy and Chien, Anna},
  title = {Racial, ethnic, and biologic sex disparities in outpatient laboratory monitoring of isotretinoin use: a cross‐sectional study},
  journal = {International Journal of Dermatology},
  year = {2024},
  doi = {10.1111/ijd.16961}
}
Kostenlos starten →